Metis TechBio, Eli Lilly Sign USD 1.1 Billion Drug Delivery Collaboration Deal
Bengaluru: Hong Kong-listed Metis TechBio said on Monday it has entered into a collaboration agreement with Eli Lilly worth up to USD 1.1 billion to research and develop tissue-specific drug delivery technologies.
The Chinese biotech will use its proprietary AI-driven drug-delivery platform to develop next-generation technologies aimed at improving how LNP-based drugs reach target tissues.
Metis will be eligible to receive an upfront payment in the low double-digit millions US dollars and up to about $1.1 billion in development, regulatory and commercial milestone payments.
It will also be eligible for tiered royalties at a single-digit percentage of annual net sales of products that are developed due to the collaboration.
The Chinese biotech will use its proprietary AI-driven ionizable lipid discovery and optimisation platform to develop delivery technologies aimed at improving the targeting and biodistribution of LNP-based therapies.
Metis and Lilly aim to discover and optimise novel LNP architectures that could improve tissue specificity and therapeutic performance, with potential applications across multiple disease areas.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.